Literature DB >> 6450628

Effect of p-chlorophenylalanine on the acquisition of tolerance to the hypnotic effects of pentobarbital, barbital, and ethanol.

J M Khanna, H Kalant, A D Lê, J Mayer, A E LeBlanc.   

Abstract

Rats were given pentobarbital by daily intubation. Sleeping times and blood levels of drug at awakening, after intraperitoneal test doses of ethanol, pentobarbital, or barbital, were measured at various times during chronic treatment in order to assess the degree of tolerance developed. No central nervous system (CNS) tolerance to pentobarbital or cross-tolerance to barbital or ethanol occurred on treatment with sodium pentobarbital, 50 mg/kg, daily. However, when the size and frequency of pentobarbital treatment doses were increased (50-80 mg/kg, three times daily) a clear CNS tolerance to barbital occurred. Chronic administration of p-chlorophenylalanine (p-CPA), in a dose previously shown to maintain more than 95% depletion of brain serotonin (5-HT), enhanced the acute hypnotic effect of barbiturates and ethanol. Independently of this effect, p-CPA treatment also resulted in a reduction in the development of CNS tolerance. These results are consistent with earlier findings that brain 5-HT depletion retards tolerance development to central depressant drugs as measured by a variety of unrelated tests.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6450628     DOI: 10.1139/y80-156

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

1.  Effect of raphe lesions on the development of chronic tolerance to pentobarbital and cross-tolerance to ethanol.

Authors:  J M Khanna; C Campanelli; A D Lê; H Kalant
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Potentiating effects of L-type Ca(2+) channel blockers on pentobarbital-induced hypnosis are influenced by serotonergic system.

Authors:  X Zhao; X-Y Cui; Q-P Chu; B-Q Chen; X-M Wang; Z-B Lin; X-J Li; B-S Ku; Y-H Zhang
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.